SEI Investments’s Adicet Bio ACET Stock Holding History

SEI Investments’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,938	Closed	-$58.6K	–	2617
2023 Q4	$58.6K	Buy	+1,938	New	+$42.3K	﹤0.01%	2548

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SEI Investments's ACET Position: Q1 2024 in Review

SEI Investments sold out of Adicet Bio (ACET) in Q1 2024, closing a stake of 1,938 shares — an estimated $58.6K sold.

SEI Investments first reported a position in ACET in Q4 2023 and held it in 1 quarter. The position peaked at $58.6K in Q4 2023. 96 funds tracked by Wall St. Rank hold ACET as of Q1 2024.

SEI Investments reported no remaining Adicet Bio position as of Q1 2024 after selling out during the quarter.
SEI Investments sold 1,938 Adicet Bio shares in Q1 2024, an estimated $58.6K.
SEI Investments first reported a position in Adicet Bio in Q4 2023 and held it in 1 quarter.
SEI Investments's Adicet Bio position peaked at $58.6K in Q4 2023.
96 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2024.

Based on SEI Investments's 13F filing for Q1 2024, filed 7 May 2024.